Overview

Safety and Efficacy of Converting Maintenance Kidney and Liver Transplant Recipients With Abnormal Glucose Metabolism From Tacrolimus to Cyclosporine Micro-emulsion

Status:
Terminated

Trial end date:
2005-10-01

Target enrollment:

Participant gender:

Summary

New onset diabetes mellitus (NODM) post- transplantation decreases patient and graft survival. Some immunosuppressive agents are associated with a higher incidence of NODM. This study evaluates the safety and efficacy of converting patients with NODM from tacrolimus to cyclosporine micro-emulsion as a primary immunosuppressant for kidney and liver recipients.

Phase:

Phase 4

Details

Lead Sponsor:

Novartis

Treatments:

Cyclosporine
Cyclosporins
Tacrolimus